Relapse Rates and Predictors for Relapse in Ulcerative Colitis and Crohn’s Disease Patients After Discontinuation of Vedolizumab or Ustekinumab: The REVEUS Study https://t.co/vUfkXVGYoF #mdpijcm via @JCM_MDPI
Type 2 #Diabetes Mellitus in #Inflammatory Bowel Disease Patients: A Case–Control Study Through a Long Follow-Up Period https://t.co/DdfHS25Kjs #mdpijcm via @JCM_MDPI
💥 New Podcast Episode
@Sciencythoughts interviewed @CeliaEscuderoHe on their molecular study which dives into the pathogenesis of lymphocytic colitis
🔗 https://t.co/m9WbJ3GHZ8
🔗 https://t.co/skEQejZJPA
💥New Podcast Edition
@Sciencythoughts interviewed Mathias Brugel from France on their study investigating the association of organochlorine pesticides and pancreatic adenocarcinoma which show a positive correlation.
https://t.co/O2z9i1Rxif
🔗 to 📄 https://t.co/J9ALUYAdDX
✴️ First comprehensive study on pancreatitis in ages 0-19 (1990-2019)
•Incidence/prevalence rising
•Mortality/DALY rates declining
•Prevention critical
https://t.co/ggZBEFgG2Z
🆕 Episode
✴️ @Sciencythoughts & @htkani interviewed Asa Frandemark on her best paper award winning study investigating work productivity & activity impairment in DGBI disorders which evaluated data from the Rome Foundation Global Epidemiology Study
🔗 https://t.co/A7GMR7DHxJ
🆕 in UEG Journal
Impact of Chemotherapy on Myenteric plexus
✴️ No inflammation or neuron changes 9–26 weeks post-chemoradiotherapy
⬆️ Increased nitrergic activity over cholinergic
⏬ Reduced muscle function, prokinetic drug efficacy
🔗 https://t.co/4v44nBpUXu
🆕 in UEG Journal
☀️ PJS polyps may be responsive to immune therapy.
✴️ CD80 and MDSCs present promising therapeutic targets for immune therapy in PJS patients.
@joostphdrenth@my_ueg
🔗 https://t.co/3GhYQaM9Qb